Innate Pharma saw the highest growth of 2.49% in patent filings and 2.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.49% and grants by 2.99%. GlobalData’s DataBook provides a comprehensive analysis of Innate Pharma‘s patent filings and grants. Buy the databook here.
Innate Pharma has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 55% filings and 60% grants. The United States(US), European Patent Office(EPO), Australia(AU), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Innate Pharma is filings its patents. Among the top granted patent authorities, Innate Pharma has 60% of its grants in United States(US), 20% in European Patent Office(EPO) and 20% in Australia(AU).
Roche could be the strongest competitor for Innate Pharma
Patents related to rare diseases and cell & gene therapy lead Innate Pharma's portfolio
Innate Pharma has the highest number of patents in rare diseases followed by, cell & gene therapy. For rare diseases, nearly 100% of patents were filed and 67% of patents were granted in Q2 2024.
Lymphoma related patents lead Innate Pharma portfolio followed by lung cancer, and mycosis fungoides
Innate Pharma has highest number of patents in lymphoma followed by lung cancer, mycosis fungoides, sezary syndrome, and head and neck cancer. For lymphoma, nearly 12% of patents were filed and 14% of patents were granted in Q2 2024.
For comprehensive analysis of Innate Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.